Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo

Journal of Urology

Volumn 164, Issue 3 I, 2000, Pages 820-825

  Liu, Xin Hua ^a   Kirschenbaum, Alexander ^a   Yao, Shen ^a   Lee, Richard ^a   Holland, James F ^a   Levine, Alice C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; Cyclooxygenase 2; NS398; Prostate cancer

Indexed keywords

CYCLINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; INOCULATION; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME; WESTERN BLOTTING;

EID: 0001501848     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)67321-1     Document Type: Article

References (28)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1996. CA Cancer J Clin, 46: 5, 1996
2. Folkman, J.: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst, 82: 4, 1992
3. Kirschenbaum, A., Wang, J. P., Ren, M. Y., Schiff, S. A., Droller, M. J., Ferrara, N., Holland, J. F. and Levine, A. C.: Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. Urol Oncology, 3: 3, 1997
4. Herschman, H. R.: Primary response genes induced by growth factors and tumor promoters. Ann Rev Biochem, 60: 281, 1991
5. Taketo, M. M.: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst, 90: 1609, 1998
6. Simmons, D. L., Levy, D. B., Yannoni, Y. and Erikson, R. L.: Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci USA, 86:1178, 1989
7. Kujubu, D. A., Flecher, B. S., Varnum, B. C., Lim, R. W. and Herschman, H. R.: TIS10, a phorbol ester tumor promoter-inducible mRNA from swiss 3T3 cells encodes prostaglandin synthase/cyclooxygenase homologue. J Biol Chem, 166: 12866, 1991
8. Xie, W. L., Robertson, D. L. and Simmons, D. L.: Mitogen-inducible prostaglandin G/H synthase: a target for NSAIDs. Drug Dev Res, 25: 249, 1991
9. Tsujii, M., DuBois, R. N.: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493, 1995
10. Tsujii, M., Kawano, S., Tsuji, S, Sawaoka, H., Hori, M. and DuBois, R. N.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705, 1998
11. Schmedtji, J. F., Jr., Ji, Y. S., Liu, W. L., DuBois, R. N. and Runge, M. S.: Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem., 272: 601, 1997
12. Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R., Morrow, J., Beauchamp, R. D. and DuBois, R. N.: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest, 99: 2254, 1997
13. Kawamori, T., Rao, C. V., Seibert, K and Reddy, B. S.: Chemo-preventive activity of celecoxib, a specific cyclooxgenase-2 inhibitor, against colon carcinogenesis. Cancer Res, 58: 409, 1998
14. Liu, X. H., Yao, S., Kirschenbaum, A. and Levine, A. C.: NS398, a selective cyclooxy-genase-2 inhibitor, induces apoptosis and down-regulation bcl-2 expression hi LNCaP cells. Cancer Res, 58: 4245, 1998
15. Houck, K A., Ferrara, N., Winer, J., Cachianes, G., Li, B. and Leung, D. W.: The vascular endothelial growth factor family: identification of a fourth molecular species and characteriza-tion of alternative splicing of RNA. Mol Endocrinol, 5: 1806, 1991
16. Futaki, N., Yoshikawa, K., Hamasaka, Y., Arai, I., Higuchi, S., Iizuka, H. and Otomo, S.: NS398, a novel non-steroidal antiinflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol, 24: 105, 1993
17. Masferrer, JL., Zweifei, BS., Manning, PT., Hauser, SD., Leahy, KM., Smith, WG., Isakson, PC. and Seibert, K.: Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA, 91: 3228, 1994
18. Rose, D. P., Connolly, J. M. and Meschter, C. L.: Effect of dietary fat on human breast cancer growth and metastasis in nude mice. J Natl Cancer Inst, 83: 1491, 1991
19. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W. and Folkman, J.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol, 143: 401, 1993
20. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R. and Folkman, J.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277, 1997
21. Ferrara, N. and Davis-Smyth, T.: The biology of vascular endothelial growth factor. Endocrine Rev, 18: 4, 1997
22. v-src - transformed 3T3 fibroblasts. Proc Natl Acad Sci USA, 87: 3373, 1990
23. Tsujii, M., Kawano, S. and DuBois, R. N.: Cyclooxygenase-2 expression in colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA, 94: 3336, 1997
24. Denmeade, S. R., Lin, X. S. and Isaacs, J. T.: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 2516, 1996
25. Berges, R. S., Vukanovic, J., Epstein, J. I., Carmichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. H. and Isaacs, J. T.: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res, 1: 473, 1995
26. Dameron, K. M., Volpert, O. V., Tainsky, M. A. and Bouck, N.: Control of angiogenesis in fibroblast by p53 regulation of thrombospondin-1. Science, 265: 1582, 1994
27. O'Reilly, M. S.: Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS, 79: 273, 1997
28. Kalgutkar, A. S., Crews, B. C., Rowlinson, S. W., Garner, C., Seibert, K, Marnett, J.: Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science, 280: 1268, 1998